Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy

Acta Oncol. 2019 Jun;58(6):888-890. doi: 10.1080/0284186X.2019.1585943. Epub 2019 Mar 8.

Affiliations

¹ a Hematology Unit, Saint' Eugenio Hospital, Tor Vergata University of Rome , Rome , Italy.
² b Neuro Oncohematology Unit, Santa Lucia Foundation and Department of Biomedicine and Prevention , Tor Vergata University of Rome , Rome , Italy.
³ c Department of Pathology , Saint' Eugenio Hospital , Rome , Italy.

PMID: 30848978
DOI: 10.1080/0284186X.2019.1585943

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Myelodysplastic Syndromes / diagnosis
Neoplasms, Multiple Primary / diagnosis
Neoplasms, Multiple Primary / drug therapy*
Remission Induction
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax